Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
46.8M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
4.55M
-
Shares change
-
-3.42M
-
Total reported value, excl. options
-
$8.59M
-
Value change
-
-$17.6M
-
Put/Call ratio
-
0.01
-
Number of buys
-
36
-
Number of sells
-
-31
-
Price
-
$1.89
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) as of Q4 2024
85 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share as of Q4 2024.
Outlook Therapeutics, Inc. - Common Stock, $0.01 par value per share (OTLK) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.55M shares
of 46.8M outstanding shares and own 9.72% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (1.09M shares), VANGUARD GROUP INC (853K shares), GEODE CAPITAL MANAGEMENT, LLC (347K shares), UBS Group AG (287K shares), STATE STREET CORP (249K shares), RHUMBLINE ADVISERS (188K shares), TANG CAPITAL MANAGEMENT LLC (183K shares), FMR LLC (182K shares), Woodline Partners LP (152K shares), and RENAISSANCE TECHNOLOGIES LLC (130K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.